- 5-HT7receptor modulators: Amino groups attached to biphenyl scaffold determine functional activity
-
5-HT7receptor (5-HT7R) agonists and antagonists have been reported to be used for treatment of neuropathic pain and depression, respectively. In this study, as a novel scaffold for 5-HT7R modulators, we designed and prepared a series of biphenyl-3-yl-methanamine derivatives with various amino groups. Evaluation of functional activities as well as binding affinities of the title compounds identified partial agonists (EC50?=?0.55–3.2?μM) and full antagonists (IC50?=?5.57–23.1?μM) depending on the amino substituents. Molecular docking study suggested that the ligand-based switch in functional activity from agonist to antagonist results from the size of the amino groups and thereby different binding modes to 5-HT7R. In particular, interaction of the ligand with Arg367 of 5-HT7R is shown to differentiate agonists and antagonists. In the pharmacophore model study, two distinct pharmacophore models can tell whether a ligand is an agonist or an antagonist. Taken together, this study provides valuable information for designing novel compounds with selective agonistic or antagonistic properties against 5-HT7R.
- Kim, Youngjae,Park, Hyeri,Lee, Jeongeun,Tae, Jinsung,Kim, Hak Joong,Min, Sun-Joon,Rhim, Hyewhon,Choo, Hyunah
-
-
Read Online
- Biphenyl derivatives acting on 5-HT7 receptor, preparation method thereof, and pharmaceutical composition comprising the same
-
The present invention relates to a biphenyl compound exhibiting pharmaceutical activity to central nervous system diseases by acting on a 5-HT7 receptor, or to a pharmaceutically acceptable salt thereof, a preparation method of the compounds, and to a pharmaceutical composition comprising the compounds as active components.COPYRIGHT KIPO 2017
- -
-
-
- Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
-
The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I): wherein: (a) m is an integer 0 or 1; (b) R12 is an alkyl, a substituted alkyl, a cycloalkyl, a substituted cycloalkyl, a heterocyclic, a substituted heterocyclic, a heteroaryl, a substituted heteroaryl, an aryl or a substituted aryl residue; (c) Ar3 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (d) Ar4 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (e) R5 is hydrogen, hydroxy, alkyl or substituted alkyl; (f) - - - - - represents a bond present or absent; and (g) W, X, Y and Z are independently or together C(O)—, C(S), S, O, or NH; or a pharmaceutically acceptable salt thereof.
- -
-
-